Form 4: DENTSPLY SIRONA Director Acquires Phantom Stock

DENTSPLY SIRONA Inc. Director Jonathan Jay Mazelsky acquired 2,644.6402 shares of phantom stock, representing the economic equivalent of common stock, on March 31, 2026.

Summary

• Jonathan Jay Mazelsky, a Director at DENTSPLY SIRONA Inc., acquired 2,644.6402 shares of phantom stock on March 31, 2026.
• These phantom stock shares are economically equivalent to common stock and will be payable in common stock upon the reporting person's termination of service as a director.
• The acquisition is part of a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard director compensation and equity grant rather than a significant new strategic development or financial performance indicator.

Positives

• Director Mazelsky's acquisition of phantom stock indicates continued commitment and alignment with the company's long-term performance.
• The transaction was made under a Rule 10b5-1(c) plan, suggesting a pre-determined and structured approach to equity ownership, which can be viewed positively by investors.

Future Outlook

The phantom stock becomes payable in common stock upon the reporting person's termination of service as a director, indicating a future conversion of these economic rights into actual shares.

Industry Context

StockSavvy.ai notes that director equity awards, such as phantom stock, are a common practice in the medical technology and dental equipment industry to incentivize long-term leadership commitment and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of phantom stock by a director can be seen as a positive signal of management's long-term commitment, potentially aligning their interests with shareholders.

Next Steps

• The phantom stock will be settled in common stock upon Director Mazelsky's termination of service.

Key Dates

Keywords

DENTSPLY SIRONA, XRAY, Form 4, Insider Trading, Phantom Stock, Director Compensation, Equity Award, SEC Filing